Major weight-loss drugs are seeing increased uptake and interest and those who use them are spending less when shopping for food, according to Morgan Stanley.
An updated Numerator survey of 92K people showed that 12.3% of households indicated that they had a member taking GLP-1s like Novo Nordisk's (NVO) Ozempic and Wegovy and Eli Lilly's (NYSE:LLY) Mounjaro and…